[May 16, 2014]

Research and Markets: Teva Pharmaceuticals' Azilect (Parkinson's Disease) Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/6296cv/azilect) has announced the addition of the "Azilect (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but severl unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain.

Azilect (rasagiline) is a second-generation MAO-B inhibitor, developed by Teva Pharmaceuticals for the treatment of the signs and symptoms of Parkinson's disease. Azilect is approved for use as a monotherapy in early Parkinson's disease at a once-daily dosage of 1mg, or as an adjunctive therapy to levodopa at 0.5mg or 1mg, as needed, once daily (Azilect package insert, 2012).

Scope

• Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Azilect including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Azilect for the top seven countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Azilect (rasagiline)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/6296cv/azilect

[ Back To TMCnet.com's Homepage ]